Search

Displaying results 1011 - 1020 of 7554 in total
  1. Drug

    Teclistamab

    go.drugbank.com/drugs/DB16655
    ApprovedInvestigational

    [L43612] Teclistamab was later granted accelerated approval by the FDA on October 25, 2022.[L43617] … cells to promote T cell–mediated cytotoxicity.

  2. Drug

    N-Acetylglucosamine

    go.drugbank.com/drugs/DB00141
    ApprovedInvestigationalNutraceutical

    The N-acetyl derivative of glucosamine.

    Mixtures: Cheon Shim Bo YunSynonyms: N-Acetylchitosamine, N-Acetylglucosamine
  3. Drug

    Zinc sulfate

    go.drugbank.com/drugs/DB09322
    ApprovedInvestigational

    It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.

    Mixtures: Clear Eyes Acr By Murine, Neo-vites & Minerals TabProducts: ZINC GO FORTE
  4. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.

  5. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    [L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones … [A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout.

  6. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and … [L54783] Aficamten works by attenuating myocardial hypercontractility and left ventricular outflow tract obstruction, which are characteristics of oHCM.[A275293]

    Synonyms: (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide, (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide
  7. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986] … of metastatic RET-fusion positive non-small cell lung cancer.

  8. Drug

    Minoxidil

    go.drugbank.com/drugs/DB00350
    ApprovedInvestigational

    A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.

    Categories: Arteriolar Smooth Muscle, Agents Acting OnProducts: GOOD GUY Mens Hair Regrowth Treatment, Polaris Research NR-02 Hair Regrowth
  9. Drug

    Halazepam

    go.drugbank.com/drugs/DB00801
    ApprovedIllicitWithdrawn

    [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229] … [A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam.

  10. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and … Casimersen is currently marketed under the tradename AMONDYS 45™ by Sarepta Therapeutics, Inc.[L32118]